Recommendations for acquisition, interpretation and reporting of whole body low dose CT in patients with multiple myeloma and other plasma cell disorders: a report of the IMWG Bone Working Group

Lia A. Moulopoulos; Vassilis Koutoulidis; Jens Hillengass; Elena Zamagni; Jesus D. Aquerreta; Charles L. Roche; Suzanne Lentzsch; Philippe Moreau; Michele Cavo; Jesus San Miguel; Meletios A. Dimopoulos; S. Vincent Rajkumar; Brian G.M. Durie; Evangelos Terpos; Stefan Delorme

doi:10.1038/s41408-018-0124-1

Recommendations for acquisition, interpretation and reporting of whole body low dose CT in patients with multiple myeloma and other plasma cell disorders: a report of the IMWG Bone Working Group

Lia A. Moulopoulos, Vassilis Koutoulidis, Jens Hillengass, Elena Zamagni, Jesus D. Aquerreta, Charles L. Roche, Suzanne Lentzsch, Philippe Moreau, Michele Cavo, Jesus San Miguel, Meletios A. Dimopoulos, S. Vincent Rajkumar, Brian G.M. Durie, Evangelos Terpos, Stefan Delorme

Hematology

Research output: Contribution to journal › Article › peer-review

23 Scopus citations

Abstract

Whole Body Low Dose CT (WBLDCT) has important advantages as a first-line imaging modality for bone disease assessment in patients with plasma cell disorders and has been included in the 2014 International Myeloma Working Group (IMWG) criteria for multiple myeloma (MM) definition. Nevertheless, standardization guidelines for the optimal use of WBLDCT in MM patients are still lacking, preventing its more widespread use, both in daily practice and clinical trials. The aim of this report by the Bone Group of the IMWG is to provide practical recommendations for the acquisition, interpretation and reporting of WBLDCT in patients with multiple myeloma and other plasma cell disorders.

Original language	English (US)
Article number	95
Journal	Blood cancer journal
Volume	8
Issue number	10
DOIs	https://doi.org/10.1038/s41408-018-0124-1
State	Published - Oct 1 2018

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1038/s41408-018-0124-1

Cite this

Moulopoulos, L. A., Koutoulidis, V., Hillengass, J., Zamagni, E., Aquerreta, J. D., Roche, C. L., Lentzsch, S., Moreau, P., Cavo, M., Miguel, J. S., Dimopoulos, M. A., Rajkumar, S. V., Durie, B. G. M., Terpos, E., & Delorme, S. (2018). Recommendations for acquisition, interpretation and reporting of whole body low dose CT in patients with multiple myeloma and other plasma cell disorders: a report of the IMWG Bone Working Group. Blood cancer journal, 8(10), Article 95. https://doi.org/10.1038/s41408-018-0124-1

Recommendations for acquisition, interpretation and reporting of whole body low dose CT in patients with multiple myeloma and other plasma cell disorders: a report of the IMWG Bone Working Group. / Moulopoulos, Lia A.; Koutoulidis, Vassilis; Hillengass, Jens et al.
In: Blood cancer journal, Vol. 8, No. 10, 95, 01.10.2018.

Research output: Contribution to journal › Article › peer-review

Moulopoulos, LA, Koutoulidis, V, Hillengass, J, Zamagni, E, Aquerreta, JD, Roche, CL, Lentzsch, S, Moreau, P, Cavo, M, Miguel, JS, Dimopoulos, MA, Rajkumar, SV, Durie, BGM, Terpos, E & Delorme, S 2018, 'Recommendations for acquisition, interpretation and reporting of whole body low dose CT in patients with multiple myeloma and other plasma cell disorders: a report of the IMWG Bone Working Group', Blood cancer journal, vol. 8, no. 10, 95. https://doi.org/10.1038/s41408-018-0124-1

@article{8f9a6bc9c4c0481ebce4cd50d4fbeeaa,

title = "Recommendations for acquisition, interpretation and reporting of whole body low dose CT in patients with multiple myeloma and other plasma cell disorders: a report of the IMWG Bone Working Group",

abstract = "Whole Body Low Dose CT (WBLDCT) has important advantages as a first-line imaging modality for bone disease assessment in patients with plasma cell disorders and has been included in the 2014 International Myeloma Working Group (IMWG) criteria for multiple myeloma (MM) definition. Nevertheless, standardization guidelines for the optimal use of WBLDCT in MM patients are still lacking, preventing its more widespread use, both in daily practice and clinical trials. The aim of this report by the Bone Group of the IMWG is to provide practical recommendations for the acquisition, interpretation and reporting of WBLDCT in patients with multiple myeloma and other plasma cell disorders.",

author = "Moulopoulos, {Lia A.} and Vassilis Koutoulidis and Jens Hillengass and Elena Zamagni and Aquerreta, {Jesus D.} and Roche, {Charles L.} and Suzanne Lentzsch and Philippe Moreau and Michele Cavo and Miguel, {Jesus San} and Dimopoulos, {Meletios A.} and Rajkumar, {S. Vincent} and Durie, {Brian G.M.} and Evangelos Terpos and Stefan Delorme",

note = "Publisher Copyright: {\textcopyright} 2018, The Author(s).",

year = "2018",

month = oct,

day = "1",

doi = "10.1038/s41408-018-0124-1",

language = "English (US)",

volume = "8",

journal = "Blood cancer journal",

issn = "2044-5385",

publisher = "Nature Publishing Group",

number = "10",

}

TY - JOUR

T1 - Recommendations for acquisition, interpretation and reporting of whole body low dose CT in patients with multiple myeloma and other plasma cell disorders

T2 - a report of the IMWG Bone Working Group

AU - Moulopoulos, Lia A.

AU - Koutoulidis, Vassilis

AU - Hillengass, Jens

AU - Zamagni, Elena

AU - Aquerreta, Jesus D.

AU - Roche, Charles L.

AU - Lentzsch, Suzanne

AU - Moreau, Philippe

AU - Cavo, Michele

AU - Miguel, Jesus San

AU - Dimopoulos, Meletios A.

AU - Rajkumar, S. Vincent

AU - Durie, Brian G.M.

AU - Terpos, Evangelos

AU - Delorme, Stefan

PY - 2018/10/1

Y1 - 2018/10/1

N2 - Whole Body Low Dose CT (WBLDCT) has important advantages as a first-line imaging modality for bone disease assessment in patients with plasma cell disorders and has been included in the 2014 International Myeloma Working Group (IMWG) criteria for multiple myeloma (MM) definition. Nevertheless, standardization guidelines for the optimal use of WBLDCT in MM patients are still lacking, preventing its more widespread use, both in daily practice and clinical trials. The aim of this report by the Bone Group of the IMWG is to provide practical recommendations for the acquisition, interpretation and reporting of WBLDCT in patients with multiple myeloma and other plasma cell disorders.

AB - Whole Body Low Dose CT (WBLDCT) has important advantages as a first-line imaging modality for bone disease assessment in patients with plasma cell disorders and has been included in the 2014 International Myeloma Working Group (IMWG) criteria for multiple myeloma (MM) definition. Nevertheless, standardization guidelines for the optimal use of WBLDCT in MM patients are still lacking, preventing its more widespread use, both in daily practice and clinical trials. The aim of this report by the Bone Group of the IMWG is to provide practical recommendations for the acquisition, interpretation and reporting of WBLDCT in patients with multiple myeloma and other plasma cell disorders.

UR - http://www.scopus.com/inward/record.url?scp=85054444473&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054444473&partnerID=8YFLogxK

U2 - 10.1038/s41408-018-0124-1

DO - 10.1038/s41408-018-0124-1

M3 - Article

C2 - 30287814

AN - SCOPUS:85054444473

SN - 2044-5385

VL - 8

JO - Blood cancer journal

JF - Blood cancer journal

IS - 10

M1 - 95

ER -

Recommendations for acquisition, interpretation and reporting of whole body low dose CT in patients with multiple myeloma and other plasma cell disorders: a report of the IMWG Bone Working Group

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this